PMC5682071_01
Magnetic resonance imaging findings at the initial visit. (a) T1-weighted fat suppression gadolinium-enhanced image (axial view). (b) T1-weighted fat suppression gadolinium-enhanced image (sagittal view). This MRI showed a large lobulated lesion with strong enhancement. The tumor was located at the abdominal wall, bulging to the lumbar spine.
CRIONM2017-3738562.001.jpg
PMC5682071_01_CRIONM2017-3738562.001.jpg
fig1
T1- and T2-weighted images, suggesting flow void. The tumor was located at the abdominal wall, bulging to the lumbar spine (Figure 1).
Enhanced computed tomography findings at the initial visit. CT revealed marked dot-like enhancement at the arterial phase, suggesting abundant vascular formation.
CRIONM2017-3738562.002.jpg
PMC5682071_01_CRIONM2017-3738562.002.jpg
fig2
Enhanced CT revealed marked dot-like enhancement at the arterial phase, suggesting abundant vascular formation (Figure 2).
Magnetic resonance imaging findings (T1-weighted fat suppression gadolinium-enhanced image). (a) After four courses of IFM/DXR. (b) After 31 months of pazopanib administration. It was classified as no change by the RECIST criteria; however, slight tumor reduction and a decrease of enhancement were observed after 31 months of pazopanib administration.
CRIONM2017-3738562.003.jpg
PMC5682071_01_CRIONM2017-3738562.003.jpg
fig3
In comparison with the MRI obtained after the initial chemotherapy regimen, the response was defined as stable disease by the RECIST criteria; however, slight tumor reduction and a decrease of enhancement were observed after 31 months of pazopanib administration (Figures 3 and 3).
Computed tomography findings. (a) After four courses of IFM/DXR. (b) After 31 months of pazopanib administration. It was classified as no change by the RECIST criteria; however, slight tumor reduction was observed after 31 months of pazopanib administration.
CRIONM2017-3738562.004.jpg
PMC5682071_01_CRIONM2017-3738562.004.jpg
fig4
Chest CT also showed slight reduction of the lung metastases after 34 months of pazopanib administration (Figures 4 and 4).
Head magnetic resonance imaging findings (T1-weighted fat suppression gadolinium-enhanced image) after 35 months of pazopanib administration. This MRI showed brain metastases with surrounding edema and a midline shift.
CRIONM2017-3738562.005.jpg
PMC5682071_01_CRIONM2017-3738562.005.jpg
fig5
At this time, brain CT and MRI revealed multiple brain metastases, with surrounding edema and a midline shift (Figure 5).
Magnetic resonance imaging findings (T1-weighted fat suppression gadolinium-enhanced image) after a drug holiday for six weeks. Tumor regrowth with increased enhancement was observed.
CRIONM2017-3738562.006.jpg
PMC5682071_01_CRIONM2017-3738562.006.jpg
fig6
A drug holiday for six weeks was needed, after which tumor regrowth was observed (Figure 6).